Literature DB >> 9846646

Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome p450-derived arachidonate metabolites.

A O Oyekan1, J C McGiff.   

Abstract

1. We tested the hypothesis that nitric oxide (NO) exerts a tonic inhibitory influence on cytochrome P450 (CYP450)-dependent metabolism of arachidonic acid (AA). 2. N(omega)-nitro-L-Arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase (NOS), increased mean blood pressure (MBP), from 91+/-6 to 137+/-5 mmHg, renal vascular resistance (RVR), from 9.9+/-0.6 to 27.4+/-2.5 mmHg ml(-1) min(-1), and reduced renal blood flow (RBF), from 9.8+/-0.7 to 6.5+/-0.6 ml min(-1)) and GFR from 1.2+/-0.2 to 0.6+/-0.2 ml 100 g(-1) min(-1)) accompanied by diuresis (UV, 1.7+/-0.3 to 4.3+/-0.8 microl 100 g(-1) min (-1)), and natriuresis (U(Na)V, 0.36+/-0.04 to 1.25+/-0.032 micromol 100 g(-1) min(-1)). 3. 12, 12 dibromododec-enoic acid (DBDD), an inhibitor of omega hydroxylase, blunted L-NAME-induced changes in MBP, RVR, UV and U(Na)V by 63+/-8, 70+/-5, 45+/-8 and 42+/-9%, respectively, and fully reversed the reduction in GFR by L-NAME. Clotrimazole, an inhibitor of the epoxygenase pathway of CYP450-dependent AA metabolism, was without effect. 4. BMS182874 (5-dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfo namide), an endothelin (ET)A receptor antagonist, also blunted the increases in MBP and RVR and the diuresis/natriuresis elicited by L-NAME without affecting GFR. 5. Indomethacin blunted L-NAME-induced increases in RVR, UV and U(Na)V. BMS180291 (1S-(1alpha,2alpha,3alpha,4alpha)]-2-[[3-[4-[(++ +pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl ]methyl]benzenepropanoic acid), an endoperoxide receptor antagonist, attenuated the pressor and renal haemodynamic but not the renal tubular effects of L-NAME. 6. In conclusion, the renal functional effects of the CYP450-derived mediator(s) expressed after inhibition of NOS with L-NAME were prevented by inhibiting either CYP450 omega hydroxylase or cyclooxygenase or by antagonizing either ET(A) or endoperoxide receptors. 20-hydroxyeicosatetraenoic acid (20-HETE) fulfils the salient properties of this mediator.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846646      PMCID: PMC1565677          DOI: 10.1038/sj.bjp.0702171

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

Review 1.  A new class of lipid mediators: cytochrome P450 arachidonate metabolites.

Authors:  M A Carroll; J C McGiff
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

3.  Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice.

Authors:  Mohammed A Nayeem; Samuel M Poloyac; John R Falck; Darryl C Zeldin; Catherine Ledent; Dovenia S Ponnoth; Habib R Ansari; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-19       Impact factor: 4.733

4.  Contribution of renal purinergic receptors to renal vasoconstriction in angiotensin II-induced hypertensive rats.

Authors:  Martha Franco; Rocio Bautista; Edilia Tapia; Virgilia Soto; José Santamaría; Horacio Osorio; Ursino Pacheco; L Gabriela Sánchez-Lozada; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-02

5.  Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride.

Authors:  A O Oyekan; T Youseff; D Fulton; J Quilley; J C McGiff
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 6.  20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension.

Authors:  Jan M Williams; Sydney Murphy; Marilyn Burke; Richard J Roman
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

7.  Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor.

Authors:  H M Siragy; T Senbonmatsu; T Ichiki; T Inagami; R M Carey
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

8.  Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo.

Authors:  L Christofer Adding; Per Agvald; Lars I Andersson; Bror Jonzon; Janet Hoogstraate; Lars E Gustafsson
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 9.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

10.  Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat.

Authors:  Hantz C Hercule; Mong-Heng Wang; Adebayo O Oyekan
Journal:  J Physiol       Date:  2003-07-11       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.